Work

Real-world conversion surgery, survival outcomes, and safety of atezolizumab plus bevacizumab with TACE in unresectable hepatocellular carcinoma.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.e16223

Authors: Xin-Rong Yang, Yi-Jun Lu, Jian-Wen Cheng, Shi-Yu Zhang, Zhong Chen, Fei Song, Yunwei Wei, Shaung-Jian Qiu, Jia Fan, Jian Zhou

Institutions: Fudan University, Zhongshan Hospital, Affiliated Hospital of Nantong University, Ningbo No. 2 Hospital

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Natural Science Foundation of China

Awards: G163480135, G2809774017, G3723955623, G8266407362

OpenAlex ID: W7162678294

Cites:

Cited by:

Related to: